MTP Building US Commercial Ops On Edaravone
This article was originally published in PharmAsia News
Executive Summary
Japanese mid-sized firm Mitsubishi Tanabe Pharma is building up its independent US commercial operations with a view to conducting the in-house marketing of new products, starting with an ALS therapy.
You may also be interested in...
Radicava US Approval Boost To Mitsubishi As Sales Decline
The arrival of the first drug for ALS in more than 20 years in the US will also be a boost to its originator Mitsubishi Tanabe's American ambitions.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.